Large Cell Carcinoma of the Lung
Authors:
- Javier PardoJPJavier Pardo
- Ana M. Martinez-PeñuelaAMAna M. Martinez-Peñuela
- Jesús J. SolaJSJesús J. Sola
- Angel PanizoAPAngel Panizo
- Alfonso GúrpideAGAlfonso Gúrpide
- Jose M. Martinez-PeñuelaJMJose M. Martinez-Peñuela
- Maria D. LozanoMaria D. Lozano
- 1 October 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 17 (5) , 383-392
Abstract
This study aims to evaluate large cell carcinomas (LCC) of the lung with a panel of immunohistochemical markers in an attempt to identify tumors belonging to other categories. We analyzed a tissue microarray platform of 101 LCC with a panel of 31 monoclonal antibodies. The tumors were 82 (81.3%) classic LCC, 7 (6.9%) neuroendocrine LCC, 6 (5.9%) lymphoepithelioma-like LCC, 3 (2.9%) basaloid LCC, 2 (2%) clear cell LCC, and 1 (1%) LCC with rhabdoid phenotype. Characteristic classic LCC immunophenotype was loss of staining with CK5/6, CK14 positive in most squamous cell carcinoma (SCC), lack of MOC 31 positive in most adenocarcinomas, and positive immunoreactivity to EGFR, PDGFR-alpha and c-kit. 27 of 82 classic LCC (32.9%) were re-classified as adenocarcinomas, because they coexpressed TTF-1, CK7, and CK19, and were negative for p63. 31 (37.8%) of 82 classic LCC were reclassified as poorly differentiated SCC, based on their immunoreactivity with 34betaE12, p63, thrombomodulin, and CD44v6. 16 (19.5%) of 82 classic LCC correspond to undifferentiated adenosquamous carcinomas, since they displayed conflicting immunostaining for markers of both SCC and adenocarcinomas. The use of 7 immunohistochemical markers, consisting of TTF-1, CK7, CK19, p63, 34betaE12, thrombomodulin, and CD44v6, markedly reduces dramatically to less than 10%, the number of classic LCC by readily identifying cases of poorly differentiated SCCs, adenosquamous carcinoma and adenocarcinomas.Keywords
This publication has 51 references indexed in Scilit:
- Primary Mixed Squamous Carcinoma and Osteosarcoma (Carcinosarcomas) of the Lung Have a CGH Mapping Similar to Primitive Squamous Carcinomas and OsteosarcomasDiagnostic Molecular Pathology, 2008
- Tumor Suppressor FUS1 Signaling PathwayJournal of Thoracic Oncology, 2008
- Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificityLaboratory Investigation, 2006
- Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the LungJournal of Clinical Oncology, 2005
- Thrombomodulin: tumour biology and prognostic implicationsEuropean Journal of Surgical Oncology, 2005
- p63 expression in assessment of bronchioloalveolar proliferations of the lungLaboratory Investigation, 2004
- 34βE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinomaHistopathology, 2003
- Lymphoepithelioma-like Carcinoma of the Lung With a Better PrognosisAmerican Journal of Clinical Pathology, 2001
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancerVirchows Archiv, 1997